secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000950170-24-057831
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum CMO Sailaja Puttagunta resigns effective May 31; Steven Aronin to lead clinical development
--------------------------------------------------------------------------------

- CMO Sailaja Puttagunta resigns for personal reasons, effective May 31, 2024; no disagreement with company.
- Dr. Puttagunta will remain as consultant during regulatory review of oral sulopenem NDA for uncomplicated UTI.
- Steven Aronin, SVP and Head of Clinical Development, will assume leadership of development and regulatory activities.
- Transition occurs during FDA review of resubmitted NDA for oral sulopenem; potential impact on timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/0000950170-24-057831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/itrm-20240510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer